More Entropy Neurodynamics Limited news
Entropy Neurodynamics LimitedASX: ENP

$6m funding to fast track TRP-8803 clinical trial strategy

Oct 29, 2024 at 10:33 PM EDT · Issued by Entropy Neurodynamics Limited

Filed with ASX · Oct 29, 2024 at 10:33 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/dollar6m-funding-to-fast-track-trp-8803-clinical-trial-strategy

Entropy Neurodynamics Limited has released a press release.

View Attachment

6ix is checking which company filed this.

Entropy Neurodynamics Limited on 6ix

Earlier from Entropy Neurodynamics

  • Pause in TradingOct 27, 2024
  • TRP-8803 doses deemed safe by SRC following phase 1b studyOct 17, 2024
  • Preliminary Final Report Reporting AdjustmentsSep 30, 2024
  • Appendix 4E Preliminary Final ReportAug 29, 2024
  • Completion of patient dosing in maiden TRP-8803 trialAug 25, 2024

Later from Entropy Neurodynamics

  • Phase 1b determines optimal parameters for TRP-8803 useNov 18, 2024
  • Phase 1b extension results meet study objectivesDec 15, 2024
  • Positive interim results in Phase 2a TRP-8802 IBS trialDec 17, 2024
  • Appendix 4D and Half Year Report for period 31 Dec 2024Feb 26, 2025
  • TRP-8803 BED trial to commence with Swinburne this quarterApr 9, 2025
All Entropy Neurodynamics news releases↗

Follow Entropy Neurodynamics into a list and get an email when it puts out news.

Follow Entropy Neurodynamics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer